Protalix BioTherapeutics, Inc. (DE) (PLX) News
Filter PLX News Items
PLX News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
PLX News Highlights
- For PLX, its 30 day story count is now at 2.
- Over the past 21 days, the trend for PLX's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
- The most mentioned tickers in articles about PLX are MAA and RARE.
Latest PLX News From Around the Web
Below are the latest news stories about Protalix BioTherapeutics Inc that investors may wish to consider to help them evaluate PLX as an investment opportunity.
Protalix, Chiesi Global file for EU approval of PRX-102 for Fabry diseaseProtalix BioTherapeutics (NYSE:PLX) and Chiesi Global Rare Diseases, a unit of Chiesi Farmaceutici S.p.A., submitted an application via centralized procedure to the European Medicines Agency (EMA) for pegunigalsidase alfa (PRX–102) to treat adults with Fabry disease. The Marketing Authorization Application (MAA) is backed by preclinical, clinical and manufacturing data from completed and... |
Protalix BioTherapeutics to Participate in the 18th Annual WORLDSymposium™ 2022Protalix BioTherapeutics, Inc. (NYSE American: PLX) (TASE: PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx® plant cell-based protein expression system, today announced that there will be two poster presentations regarding the Company's pegunigalsidase alfa or PRX–102 candidate under development for the treatment of Fabry disease at the 18th Annual WORLDSymposium™ 2022, taking |
Protalix Biotherapeutics: Is It Worth The Wait?No summary available. |
Protalix BioTherapeutics Issues 2021 Letter to StockholdersProtalix BioTherapeutics, Inc. (NYSE American: PLX) (TASE: PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx® plant cell-based protein expression system, today announced the following letter from its President and Chief Executive Officer, Dror Bashan, to its stockholders and the investment community. |
Protalix BioTherapeutics, Inc. (NYSEAMERICAN:PLX) Shares Bought by Morgan StanleyMorgan Stanley raised its stake in Protalix BioTherapeutics, Inc. (NYSEAMERICAN:PLX) by 3,723,538.0% in the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 1,861,819 shares of the companys stock after acquiring an additional 1,861,769 shares during the period. Morgan Stanleys holdings in Protalix BioTherapeutics [] |
Protalix BioTherapeutics Inc. (AMEX: PLX): Whats Next In 2021?Protalix BioTherapeutics Inc. (AMEX:PLX) shares, rose in value on Wednesday, 11/24/21, with the stock price up by 6.10% to the previous days close as strong demand from buyers drove the stock to $1.00. Actively observing the price movement in the last trading, the stock closed the session at $0.94, falling within a range of $0.92 Protalix BioTherapeutics Inc. (AMEX: PLX): Whats Next In 2021? Read More » |
Protalix BioTherapeutics Inc (PLX): Price Now Near $0.95; Daily Chart Shows Downtrend on 100 Day BasisThe moving averages on the daily timeframe suggest a bearishness in price, as the 20, 50, 100 and 200 are all in a bearish alignment -- meaning the shorter duration moving averages are below the longer duration averages, implying a stable downward trend. The post Protalix BioTherapeutics Inc (PLX): Price Now Near $0.95; Daily Chart Shows Downtrend on 100 Day Basis appeared first on ETF Daily News . |
Protalix BioTherapeutics, Inc. (PLX) CEO Dror Bashan on Q3 2021 Results - Earnings Call TranscriptNo summary available. |
PLX: Third Quarter UpdateBy John Vandermosten, CFA NYSE:PLX READ THE FULL PLX RESEARCH REPORT Third Quarter Financial and Operational Review Protalix Biotherapeutics, Inc. (NYSE:PLX) announced its 3Q:21 financial and operational results in a November 15, 2021 press release and filing of Form 10-Q . Promulgation of the reports was followed by a pre-market conference call which discussed recent achievements. Operational |
Protalix BioTherapeutics Reports Third Quarter 2021 Financial Results and Provides Financial and Business UpdateProtalix BioTherapeutics, Inc. (NYSE American: PLX) (TASE: PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx® plant cell-based protein expression system, today reported financial results for the third quarter ended September 30, 2021 and provided a financial and business update on recent corporate, clinical and regulatory developments. |